Viking Therapeutics (VKTX) News Today

Viking Therapeutics, Inc. (NASDAQ:VKTX) saw mixed analyst actions and several Q2 updates driving today’s stock movement. Key developments include trial progress and price‐target shifts alongside a broader Q2 earnings miss.

• Positive Sentiment: Citigroup raised its VKTX price target to $38 from $31, reflecting a 13.4% upside with a “neutral” rating.Benzinga
• Positive Sentiment: Viking’s Q2 corporate update highlighted Phase 3 VANQUISH trials for VK2735 in obesity, completion of Phase 2 VENTURE oral dosing enrollment (top-line results due 2H25), ongoing Amylin program advancement (IND planned 4Q25), and a strong $808 M cash position.Press Release
• Neutral Sentiment: Analysts at Raymond James trimmed their VKTX price target slightly to $122 (from $125) but maintained a “strong-buy” stance.Benzinga
• Neutral Sentiment: Short interest data showed no reported shorted shares as of July 24, keeping the days-to-cover ratio at 0.0 days.
• Neutral Sentiment: A Reddit-based bull case on VKTX, highlighting under-the-radar growth catalysts, was detailed on InsiderMonkey.InsiderMonkey
• Neutral Sentiment: Investors can review Viking’s Q2 2025 earnings call transcript covering R&D investments and strategic guidance.Seeking Alpha
• Negative Sentiment: MarketBeat reported a Q2 EPS loss of $0.58 vs. a $(0.44) estimate and no revenue growth, underscoring investor concerns.MarketBeat
• Negative Sentiment: Zacks highlighted the wider-than-expected Q2 loss on nil sales and rising R&D, driving shares lower.Zacks
• Negative Sentiment: The Motley Fool noted Viking’s wider Q2 loss, emphasizing the EPS miss and absent revenue improvement.The Motley Fool